Business Description
Ovid Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US6904691010
Description
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 6.61 | |||||
Equity-to-Asset | 0.61 | |||||
Debt-to-Equity | 0.18 | |||||
Debt-to-EBITDA | -0.28 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 1/9 | |||||
Altman Z-Score | -0.81 | |||||
Beneish M-Score | -3.28 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -69.7 | |||||
3-Year EBITDA Growth Rate | 16.2 | |||||
3-Year EPS without NRI Growth Rate | 17.9 | |||||
3-Year FCF Growth Rate | 9.9 | |||||
3-Year Book Growth Rate | 23.2 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 44.72 | |||||
9-Day RSI | 45.64 | |||||
14-Day RSI | 46.57 | |||||
12-1 Month Momentum % | -9.26 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 9.55 | |||||
Quick Ratio | 9.55 | |||||
Cash Ratio | 9.22 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.4 | |||||
Shareholder Yield % | -0.06 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -15122.96 | |||||
Net Margin % | -13351.53 | |||||
FCF Margin % | -11731.4 | |||||
ROE % | -47.32 | |||||
ROA % | -37.18 | |||||
ROIC % | -192.11 | |||||
ROC (Joel Greenblatt) % | -385.77 | |||||
ROCE % | -44.92 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 500 | |||||
PB Ratio | 2.42 | |||||
Price-to-Tangible-Book | 2.41 | |||||
EV-to-EBIT | -2.07 | |||||
EV-to-Forward-EBIT | -5.11 | |||||
EV-to-EBITDA | -2.13 | |||||
EV-to-Revenue | 312.76 | |||||
EV-to-Forward-Revenue | 14.68 | |||||
EV-to-FCF | -2.67 | |||||
Price-to-Net-Current-Asset-Value | 4 | |||||
Price-to-Net-Cash | 4.31 | |||||
Earnings Yield (Greenblatt) % | -48.31 | |||||
FCF Yield % | -21.61 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Ovid Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 0.363 | ||
EPS (TTM) (€) | -0.695 | ||
Beta | 0.37 | ||
Volatility % | 48.02 | ||
14-Day RSI | 46.57 | ||
14-Day ATR (€) | 0.073685 | ||
20-Day SMA (€) | 2.889 | ||
12-1 Month Momentum % | -9.26 | ||
52-Week Range (€) | 2.46 - 3.68 | ||
Shares Outstanding (Mil) | 70.81 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 1 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Ovid Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Ovid Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Ovid Therapeutics Inc Frequently Asked Questions
What is Ovid Therapeutics Inc(FRA:1OT)'s stock price today?
When is next earnings date of Ovid Therapeutics Inc(FRA:1OT)?
Does Ovid Therapeutics Inc(FRA:1OT) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |